Skip to content

VOCs in Patients With Acute Cardiogenic Chest Pain

Application of Emergency Rapid Detection of Expiratory Volatile Organic Compounds (VOCs) in Patients With Acute Cardiogenic Chest Pain

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06277895
Enrollment
1400
Registered
2024-02-26
Start date
2024-01-26
Completion date
2024-12-31
Last updated
2024-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Aortic Syndrome, Acute Coronary Syndrome

Brief summary

The goal of this observation study is to compare VOCs in cardiogenic chest pain population/health conditions, to answer:Establishment and promotion of the application system of emergency rapid detection of expiratory Volatile Organic Compounds (VOCs) in patients with acute cardiogenic chest pain 1. VOCs levels were measured at baseline in healthy people, and markers of VOCs that could be used to identify acute cardiogenic chest pain were sought. 2. The relationship between abnormal VOCs (mainly aldehydes) and prognosis of patients and the correlation with Super-score for early warning of acute heart failure.

Interventions

DIAGNOSTIC_TESTVOCs

test the end-expiratory gas

Sponsors

Qilu Hospital of Shandong University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Observation group inclusion criteria: 1. Over 18 years old, male or female; 2. Patients with acute cardiogenic chest pain (see diagnostic criteria); 3. Patient's informed consent. Inclusion criteria of healthy control group: 1. Over 18 years old, male or female; 2. Centerless cerebrovascular disease, lung disease, no abnormal liver and kidney function, no acute infection recently; 3. Informed consent.

Exclusion criteria

1. The patient had difficulty in collecting breath; 2. Patients with terminal illness or receiving palliative care; 3. Have participated in other clinical studies or consider it inappropriate to participate in this study.

Design outcomes

Primary

MeasureTime frameDescription
Baseline VOCs (aldehydes) levels in healthy populationBaselineBaseline VOCs (aldehydes) levels in healthy population

Secondary

MeasureTime frameDescription
MACE in patients with cardiogenic chest painFrom enrollment to the end of treatment at 30 daysthe relationship between the different VOCs levels and 30-day MACE in patients with cardiogenic chest pain

Countries

China

Contacts

Primary ContactYuan Bian, Dr.
bianyuan@sdu.edu.cn+8618560083065
Backup ContactXiuting Yang, Dr.
yxt-1819@163.com800-872-5327

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026